Avastin is dosed at four to six-week intervals for AMD, while Eylea is given every four to eight weeks and Lucentis once a month. Novartis is developing a follow-on drug – brolucizumab – that ...

Novartis ups the ante in the wet AMD market battle with Bayer/Regeneron’s Eylea, launching a trial that will test 16-week dosing for its new antibody brolucizumab.